No Picture
News

Global Genes Report Finds Technology Reshaping the Rare Disease Landscape, but Non-Scientific Challenges Threaten to Impede Progress

Report seeks to foster creative thinking and new approaches to addressing obstacles to patients getting the answers and care they need

ALISO VIEJO, Calif., Sept. 18, 2019 /PRNewswire/ — The rapid progress of technology is creating an opportunity to … […]

No Picture
News

FDA Awards AnaBios Grant to Further Develop Preclinical Assay Using Human Primary Cardiomyocytes

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).  Fu… […]

No Picture
News

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two ind… […]

No Picture
News

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

Company expands pipeline of innovative therapies for immunocompromised patients

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening dis… […]

No Picture
News

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology

– Phase III FeDeriCa Study Met Primary Endpoint of Non-inferiority — New Subcutaneous Fixed-dose Combination Significantly Reduced Administration Time — Data to be Submitted to Health Authorities including the U.S. Food and Drug Administration and Eu… […]

No Picture
News

DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020

SAN DIEGO, Sept. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMa… […]